secwatch / observer
8-K filed January 23, 2026, 6:59 PM ET ticker JAGX CIK 0001585608
other material confidence high sentiment neutral materiality 0.60

Jaguar Health issues ~11.8M pre-funded warrants to reduce $2.04M in royalties and preferred stock

Jaguar Health, Inc.

item 1.01item 3.02item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. entered into Streeterville Royalty Interest Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock in ex (effective 2026-01-16).

Action
entry
Counterparty
Streeterville Capital, LLC
Value
Issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock in ex
Effective
2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Streeterville Royalty Interest Exchange Agreement”) with Streeterville.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. entered into Streeterville Series L Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock in ex (effective 2026-01-16).

Action
entry
Agreement
equity purchase
Counterparty
Streeterville Capital, LLC
Value
Issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock in ex
Effective
2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock (the “Fourth Pre-Funded Warrant”) to Streeterville in exchange for 99.3822 shares of Series L Preferred Stock held by Streeterville.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. entered into Streeterville Series M Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock in ex (effective 2026-01-16).

Action
entry
Agreement
equity purchase
Counterparty
Streeterville Capital, LLC
Value
Issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock in ex
Effective
2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock (the “Sixth Pre-Funded Warrant”) to Streeterville in exchange for 69.44 shares of Series M Preferred Stock held by Streeterville.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. entered into Iliad Series M Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock in ex (effective 2026-01-16).

Action
entry
Agreement
equity purchase
Counterparty
Iliad Research and Trading, L.P.
Value
Issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock in ex
Effective
2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock (the “Fifth Pre-Funded Warrant”) to Iliad in exchange for 87.78 shares of Series M Preferred Stock held by Iliad.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. entered into Iliad Royalty Interest Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock in ex (effective 2026-01-16).

Action
entry
Counterparty
Iliad Research and Trading, L.P.
Value
Issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock in ex
Effective
2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Iliad Royalty Interest Exchange Agreement”) with Iliad.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. entered into Iliad Series L Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock in exch (effective 2026-01-16).

Action
entry
Agreement
equity purchase
Counterparty
Iliad Research and Trading, L.P.
Value
Issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock in exch
Effective
2026-01-16
Exact text from the filing
On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock (the “Third Pre-Funded Warrant”) to Iliad in exchange for 22 shares of Series L Preferred Stock held by Iliad.
View on SEC.gov

308 material agreements filed in the last 30 days. Browse all material agreements →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-021064
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.